Memory Enhancement Pharmaceutical Raw Materials Sunifiram Powder
Sunifiram
(DM-235) is a piperazine derived ampakine drug which acts as a positive
allosteric modulator of AMPA receptors, and has nootropic effects in
animal studies with significantly higher potency than piracetam. A
number of related compounds are known, the best known being unifiram
(DM-232).
This enhancement by sunifiram is associated with an
increase inphosphorylation of AMPAR through activation of protein kinase
II(CaMKII) and an increase in phosphorylation of NMDAR through
activation of protein kinase C α (PKCα). More specifically, sunifiram
stimulates the glycine-binding site of NMDAR with concomitant
PKCαactivation through Src kinase. Enhancement of PKCα activity triggers
to potentiate hippocampal LTP through CaMKII activation.
Sunifiram improves cognitive deficits via CaM kinase II andprotein kinase C activation.
Applicant
Sunifiram (DM-235) is a synthetic derivative of
piracetam, although due to breaking the pyrrolidone backbone it is no
longer in the racetam class of drugs (yet by being derived from them, it
is still commonly associated with this class).Sunifiram has mechanisms
similar to nefiracetam in the hippocampus, and similar to that drug
sunifiram shows anti-amnesiac properties and is potentially a cognitive
enhancer. Its anti-amnesiac activity is several orders of magnitude
greater than piracetam on a per weight basis, and preliminary evidence
suggest it has a similarly low toxicity profile.This compound is known
as an AMPAkine due to exerting most of its actions via the AMPA receptor
(one of the three main subsets of glutamate receptors, alongside NDMA
and kainate). This enhancement of AMPA function seems to also rely on
enhancing signalling via the glycine binding site of NMDA receptors,
although one minimal signalling goes through the NMDA receptor then the
benefits on AMPA receptors seem dose-dependent.
